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There is no consensus about the hemodynamic significance and, therefore, the need 
to treat a persistent ductus arteriosus in preterm newborns. Since the diagnosis of a 
hemodynamically significant persistent ductus arteriosus (hsPDA) is made by a sum-
mary of non-uniform echo-criteria in combination with the clinical deterioration of the 
preterm neonate, standardized clinical and ultrasound scoring systems are needed. 
The objective of this study was the development of a clinical score for the detection 
and follow-up of hsPDA. In this observational cohort study of 154 preterm neonates 
(mean gestational age 28.1 weeks), clinical signs for the development of hsPDA were 
recorded in a standardized score and compared to echocardiography. Analyzing the 
significance of single score parameters compared to the diagnosis by echocardiography, 
we developed a short clinical score (calculated sensitivity 84% and specificity 80%). In 
conclusion, this clinical diagnostic PDA score is non-invasive and quickly to implement. 
The continuous assessment of defined clinical parameters allows for a more precise 
diagnosis of hemodynamic significance of PDA and, therefore, should help to detect 
preterm neonates needing PDA-treatment. The score, therefore, allows a more targeted 
use of echocardiography in these very fragile preterm neonates.
Keywords: arterial duct, clinical diagnostic score, echocardiography, ductus arteriosus Botalli, premature infants, 
very low birth weight
inTrODUcTiOn
The association of hemodynamically significant persistent ductus arteriosus (hsPDA) with intra-
ventricular hemorrhage (IVH), pulmonary hemorrhage, bronchopulmonary dysplasia (BPD), and 
intestinal complications, such as necrotizing enterocolitis (NEC), is an ongoing field of research and 
discussed controversially (1–6). There is no consensus about the diagnosis and the hemodynamic 
Abbreviations: AC, acidosis; AIS, amnion infection syndrome; A/MV, apnea or mechanical ventilation; BPD, bronchopul-
monary dysplasia; BW, birth weight; CPAP, continuous positive airway pressure; FP, femoral pulses; GA, gestational age; HM, 
hepatomegaly; HR, heart rate; hsPDA, hemodynamically significant persistent ductus arteriosus; IVH/ICH, intraventricular 
hemorrhage/intracerebral hemorrhage; NEC, necrotizing enterocolitis; PD, pulmonary deterioration; PI, postnatal infection; 
PHT, pulmonary hypertension; PP, pulsations of the precordium; PRM, premature rupture of the membrane; PVL, perive-
ntricular leukomalacia; RDS, respiratory distress syndrome; ROC, receiver operating characteristic; ROP, retinopathy of 
prematurity; SM, systolic murmur; wks, weeks of gestational age.
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significance and, therefore, the need to treat a PDA (7). In preterm 
neonates, the arterial duct often persists and stays open, due to 
immaturity, higher prostaglandin levels and hypoxia (8, 9). Due 
to the change of fetal to postnatal circulation, with a decrease in 
pulmonary resistance, the blood flow through the patent arterial 
duct inverses (from a right-to-left into a left-to-right shunt), now 
leading to a pulmonary overflow and a steal-phenomenon of the 
systemic circulation. This leads to hemodynamic instability with 
the following clinical symptoms: respiratory deterioration (RD) 
(due to increased lung perfusion), increased precordial pulsa-
tions, tachycardia, hepatomegaly (HM), accentuated femoral 
pulses (FP) (due to the ductal steel phenomenon and increased 
cardiac charge) and oliguria and metabolic acidosis (AC) (due to 
decreased systemic perfusion).
Since untreated hsPDA alters organ perfusion and potentially 
induces hypoxia in these organs (e.g., brain, kidney, bowels), 
several studies have investigated the ability of biomarkers to dis-
criminate between infants with and without hsPDA. Natriuretic 
peptides (such as BNP and NTpBNP) showed a strong predictive 
ability for early detection of an hsPDA (on days 3 and 4) in pre-
term infants (10, 11). In another clinical study, ischemia-modified 
albumin (IMA) was suggested as a new biochemical marker for the 
diagnosis and monitoring of a successful treatment of hsPDA in 
premature infants (12). A positive correlation was found between 
IMA and PDA diameter, and LA/Ao ratio (12). However, further 
studies evaluating the diagnostic accuracy of natriuretic peptides 
and IMA for detection of hsPDA showed wide variability accord-
ing to assay criteria and patient characteristics (13). Therefore, 
generalizability is limited and further studies with standardized 
methods as well as objective clinical and echocardiography 
parameters are needed.
In recent years, fewer medical interventions and more 
supportive measures such as fluid restriction (5, 14) and non-
invasive ventilatory support have been implemented to reduce 
the occurrence of hsPDA. In a recent publication, extremely 
preterm infants between 23–26 weeks with an hsPDA (defined 
as “left-to-right flow by gain-optimized color Doppler” measur-
ing ≥2  mm) requiring ventilator treatment were divided in 
two groups, “mandatory closure” with i.v. indomethacin and/
or surgical ligation versus “non-intervention approach” (fluid 
restriction and diuretics with respiratory support as needed) 
(15) and compared regarding there outcome. Surprisingly, the 
non-intervention group was reported with significantly less 
BPD despite longer PDA exposure and was not associated with 
increased mortality or morbidities such as IVH or NEC (15). 
This result could perhaps partly be explained by the high rate of 
surgical ligation (82%) in the “mandatory treatment” group, lead-
ing to a higher rate of postoperative myocardial dysfunction and 
successively higher use of inotropic drugs (15). A longer phase 
of positive pressure ventilation support in these patients as an 
additional reason for the higher rate of BPD in the “mandatory 
treatment” group could be excluded (15). However, looking at 
their data, the duration of supplemental oxygen was significantly 
higher (p <  0.05) in the “mandatory treatment” group. At this 
point, one could speculate that the oxygen induced initiation of 
inflammatory processes within the lung could play a role for the 
higher BPD rate in this group. Another speculation raced by the 
authors is the influence of more prolonged use of high-frequency 
oscillatory ventilation in the “non-intervention approach” group, 
which perhaps may have contributed to the lower BPD rate in 
this group (15).
However, despite the mentioned conservative measures there 
are still patients who develop hsPDA. But, whether and when 
such infants require treatment is still controversially discussed 
(16). Therefore, prospective randomized clinical trials of current 
pharmacological treatment “standards” (such as i.v. ibuprofen or 
i.v. indomethacin) versus “non-intervention support” are needed 
to answer the question, whether hsPDA contributes to the devel-
opment of other co-morbidities such as BPD, NEC, retinopathy 
of prematurity, and IVH. In addition, there is a need for clearly 
defined and widely applicable clinical and echocardiography 
criteria for the selection of patients with clinical relevant hsPDA 
who may benefit from ductul closure.
The aim of this study was to evaluate the reliability of a clinical 
score to predict the hemodynamic significance of the PDA, which 
should help to decide whether to perform an echocardiography.
PaTienTs anD MeThODs
study Population
This single-center observational cohort study was performed in 
a level one neonatology center. A total of 200 neonates with a 
gestational age (GA) of ≤31  weeks admitted between October 
2008 and September 2010 was screened for eligibility. 47 patients 
had to be excluded from the study because of lacking datasets. 
Therefore, 154 preterm neonates (59.7% male, 40.3% female) 
were included in the study population.
ethical approval
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable 
ethical standards. Permission for this study was approved by the 
hospital’s Human Ethics Research Committee (EK359112010).
informed consent
For this type of study informed consent was not required since 
all clinical and echocardiography examinations were routine care, 
which has been signed by the parents.
echocardiographic criteria
Echocardiographic criteria indicating hsPDA were ductus arterio-
sus diameter at its narrowest part >1.5 mm (17, 18) and at least 
one additional criteria such as absent (end-)diastolic flow in the 
celiac trunk (19, 20), maximal velocity of the left-to-right shunt 
through the PDA < 1.5 m/s (20, 21), left atrial-to-aortic root ratio 
>1.3 (19, 22–27).
Data collection
The clinical score to detect an hsPDA was based on a score 
described by Kabus (28). The original score was modified by 
deleting X-ray-results and including new clinical criteria. The new 
FigUre 1 | Flowchart of the clinical approach to diagnose a clinical relevant hemodynamically significant persistent ductus arteriosus (hsPDA) using clinical 
parameters and echocardiography. The scoring tool was used in all premature neonates equal or less than 31 weeks of gestation. In all preterm infants GA 
<28 weeks or BW <1,000 g, an initial echocardiography was performed between 48 and 72 h of life, in addition to the clinical score. All other premature neonates 
GA ≥28 weeks were assessed by clinical scoring and received an echocardiography only if the score was ≥2 points. GA, gestational age; BW, birth weight.
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scoring system consists now of the following eight clinical cri-
teria: pulsations of the precordium (PP), systolic murmur (SM), 
tachycardia [heart rate (HR)] > 160 bpm, apnea or mechanical 
ventilation (A/MV), bounding FP, HM, metabolic AC with pH 
<7.30, and base excess <−5 and RD, indicated by increased 
oxygen supplementation, increased non-invasive or invasive 
respiratory support, increased apnea frequency and mounting 
hypercapnia. For each criterion that was present, one point was 
scored. If the score reached ≥2 points, an hsPDA was suspected 
and echocardiography was performed. The score was assessed 
daily by the attending neonatologist, starting with day 2 until day 
10 of life.
The scoring tool was used in all premature neonates equal or less 
than 31 weeks of gestation. In all preterm infants, GA < 28 weeks 
or birth weight (BW) < 1,000 g, an initial echocardiography was 
performed between 48 and 72 h of life, in addition to the clinical 
score. All other premature neonates GA ≥28 weeks were assessed 
by clinical scoring and received an echocardiography only if the 
score was ≥2 points (Figure 1).
statistical analysis
Statistical analyses were performed using IBM SPSS 22.0 (IBM, 
Chicago, IL, USA). For nominal scaled parameters, absolute and 
relative frequency was determined. Correlations between two or 
TaBle 1 | Demographic data of the study population.
Demographic data sD (±)
Study population (total patients,  
% females, % males)
154 (40.3, 59.7)
Mean gestational age (weeks) 28.1 2.2
Mean gestational weight (g) 1,052 374
Mean APGAR 1 min 4 2.2
Mean APGAR 5 min 7 1.7
Mean APGAR 10 min 8 1.2
Mean umbilical artery pH 7.29 0.12
Mean duration of hospitalization (days) 71.9 35.9
Mean BW (g) at discharge 2,405 475
Preterm neonates needing respiratory support (%) 96.1
Mortality (%) 7.1
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more nominal scaled parameters were examined using the chi-
square-test (or the exact Fisher test). For that, observed versus 
expected frequencies were compared by cross-tabulation tables. 
A t-test was used for metric scaled variables and independent 
samples (normal distribution). p-Values < 0.05 were considered 
statistically significant. For comparing the quality of combina-
tions of particular features, receiver operating characteristic 
(ROC) (29) curves were used to determine the sensitivity and 
specificity by calculating the area under the curve (dependent on 
the determined cutoff level).
resUlTs
Demographic Data of the study 
Population
The mean GA of the study population (n = 154) was 28.1 weeks 
(SD ±2.2), with a mean gestational weight (GW) of 1,052 g (SD 
±374). Additional demographic data are shown in Table 1, and 
risk factors for the development of an hsPDA and the outcome 
of the study population regarding chronic sequelae are shown in 
Table S1 in Supplementary Material. None of our patients had 
major associated malformations.
An hsPDA was suspected according to clinical scoring 
in 86% of infants between the second and fourth day of life 
(mean 3.15 days). Out of the 154 included preterm neonates, 
88 patients (57.1%) were diagnosed with hsPDA by the gold 
standard of echocardiography. The incidence of hsPDA in pre-
term neonates below 28 weeks was significantly higher (74.6%) 
compared to preterm neonates between 28–31 weeks (43.7%; 
p < 0.001).
evaluation of the clinical PDa score
To evaluate the clinical PDA score including eight parameters 
(PP, HR, A/MV, FP, SM, HM, AC, PD) we compared its sensitivity 
and specificity to predict the presence of an hsPDA as diagnosed 
by echocardiography. Using logistical regression analysis and 
ROC (29) curves, we compared the strength of combining 
particular items of the score and determined its sensitivity and 
specificity. More precise, for each day (2–4) we performed logisti-
cal regression analyses of all eight clinical parameters (from the 
initial score) and tested for statistical significance. Parameters 
with p < 0.1 were used for the “new short clinical score.” Four 
parameters were included in the final model. With these four 
parameters we performed ROC analyses for comparing the 
quality of combination of the particular parameters for each day 
to predict the development of hsPDA. With the coordinates of 
the ROC curves, we determined the best cutoff-value, which has 
been 1.5. With that we calculated specificity and sensitivity for 
the clinical score.
As shown in Figure 2A, the sensitivity and specificity of this 
score increased from day 2 to day 4, and reached 88.2% sensitivity 
and 76.9% specificity.
score Parameters and Their significance
To weight single score citeria, cross-tabulation tables were used 
to contrast the single parameters with the development of an 
echocardiographic confirmed hsPDA (univariate analysis). By 
determination of the adapted residuum and the exact significance 
by the Fisher test, the significant and strongest statistical para-
meters were determined.
The test to summarize clinical parameters by logistic regression 
analysis allowed us to specify the following significant symptoms: 
pulsations of the precordium, bounding FP, apnoe/mechanical 
ventilation and metabolic AC (Table 2). On days 3 and 4 of life 
these parameters correlate most strongly with the development of 
an hsPDA verified by echocardiography.
new short clinical PDa score
With the aim to simplify this clinical scoring system further, we 
tried to reduce the number of parameters by using only the previ-
ously tested statistically significant parameters in a so-called new 
(short) PDA score. By again using logistical regression analysis 
and ROC curves, we compared the power of combinations of 
these parameters and determined the sensitivity and specificity. 
The new short clinical PDA score reached a calculated sensitivity 
of 84% and a specificity of 80% on day 4 (Figure 2B), which is 
similar to the re-established initial score.
Validity of the clinical score
In order to further increase sensitivity and specificity, we gave 
single score items a different weight. For the presence of a 
parameter, we increased the number of points from 1 to 2 or 3. 
But this did not improve the validity of the score (not shown). 
In Figure 2C, the distribution (frequency) of the given score 
points at day 4 is shown as an example. On the upper part the 
infants without hsPDA and on the lower part the ones with 
hsPDA are shown. Newborns with hsPDA usually reached a 
score of 2 or more points. The cutoff-level of the clinical score 
stayed at 2.
DiscUssiOn
Persistent ductus arteriosus is a physiological phenomenon of 
the preterm infant with a delayed closure during the first week 
of life. In preterm neonates below 28  weeks, who often need 
FigUre 2 | (a,B) Sensitivity and specificity of the clinical PDA score. Using multivariate logistic regression analysis (daily) and receiver operating characteristic (ROC) 
(29) curves, we compared the power of combinations of particular features and determined the sensitivity and specificity (dependent on the determined cutoff-level). 
The theoretical optimal cutoff-level was 1.5 points. (c) Screening of the validity of the clinical score. We tested to see if the score of ≥2 points was able to 
discriminate between the two groups with and without hsPDA. For the presence of a parameter we increased the number of points from 1 to 2 or 3. The frequency 
of the given points at day 4 of the score is shown as an example. On the upper part the infants without hsPDA are shown, those with hsPDA are shown on the 
lower part. Newborns with hsPDA usually reached a score of 2 or more points.
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ventilatory support, the prevalence of ductal patency at 48–72 h 
of life is still high [about two-thirds (30, 31)], and varies between 
centers (32). There is a higher incidence of hsPDA in small for 
GA infants (33, 34).
In accordance with published data (35), the frequency of 
hsPDA in our study population is inversely related to GA of 
preterm infants. In addition, preterm neonates initially supported 
by continuous positive airway pressure were significantly less 
likely to develop an hsPDA compared to initially mechanically 
ventilated preterm neonates [also reported by Ref. (32)].
Prior to the routine use of echocardiography in neonatol-
ogy, clinical symptoms such as bounding pulses, a hyperactive 
precordium, increased blood pressure amplitude, SM, as well as 
an increased cardiothoracic ratio on the chest X-ray were used 
for diagnosing PDA (36–38). Furthermore, the arterial duct was 
usually searched for when the infant could not be weaned from 
the respirator or cardiac failure occurred.
At present, echocardiography is the gold standard for the 
diagnosis of hsPDA, but there is not just one criterion confirming 
this diagnosis. It is rather a summary of several echo-criteria in 
6
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combination with the clinical deterioration of the preterm neonate 
allowing to confirm this diagnosis (Table S2 in Supplementary 
Material). However, clinical and echocardiography criteria are 
not uniform between centers.
Despite the general meaning that neonatal echocardiogra-
phy can be performed easily and quickly by an experienced 
specialist, this examination needs opening of the incubator 
with potential risk of hypothermia, needs several sectional 
planes and doppler measurements and is potentially disturbing 
and stressing for extremely low BW infants below 28 weeks (or 
<  1,000  g). For this reason, ultrasound examinations should 
be performed only if necessary. Therefore, a clinical score for 
the diagnosis of hsPDA potentially reduces the number of 
ultrasound examinations in such small, fragile and immature 
neonates.
Here, we investigated to what extent a new clinical scoring 
system for the detection of hsPDA is able to predict the hemo-
dynamic significance of the PDA as diagnosed by echocardi-
ography. We tested combinations of eight clinical parameters 
compared to hsPDA-diagnosis by echocardiography. As a result, 
a new scoring system composed of four significant symptoms 
(pulsations of the precordium, bounding FP, apnea/mechanical 
ventilation, and metabolic AC) was established. The new score 
reached a calculated sensitivity (84%) and specificity (80%). For 
the parameter A/MV, we adapted our clinical criteria to “pulmo-
nary deterioration” compared to the previous day, as indicated 
by increased oxygen supplementation, increased non-invasive 
or invasive respiratory support, increased apnea frequency and 
mounting hypercapnia.
To avoid over-diagnosis of hemodynamically non-significant 
(irrelevant) PDA and to reduce the number of unnecessary ultra-
sound examinations in premature neonates, an initial standard 
echocardiography was only performed in preterm neonates 
below 28  weeks or BW  <  1,000  g between 48 and 72  h of life 
(in addition to the clinical score). All premature neonates GA 
< 31 weeks were assessed by the clinical scoring system during 
the first week of life and in some cases further, and received an 
echocardiography only if the score was ≥2 points. To evaluate the 
success of this approach to reduce echocardiography numbers is 
an ongoing investigation for the new scoring system composed of 
four significant symptoms.
To determine the need for treatment in preterm neonates with 
hsPDA standardized protocols or scoring systems for the echo-
cardiography are lacking, and the comparability and repeatability 
of echocardiography in preterm infants with suspected PDA is far 
from optimal. This newly established clinical score provides the 
potential to evaluate a standardized echocardiography approach 
for diagnosing hsPDA. A follow-up cohort study to address 
this issue in preterm infants below 28 weeks is actually on the 
way. Therefore, this clinical score is developed as an addition to 
echocardiography to find more uniform criteria for the diagnosis 
of hsPDA, not to replace it.
The limitations of the presented study are the non-controlled 
observational study design and the variable echocardiography 
criteria between different neonatal care centers. Prospective 
controlled trials are needed to establish standardized protocols 
and robust echocardiography criteria for the diagnosis of hsPDA 
and the need for treatment.
In conclusion, this new clinical PDA score is non-invasive, 
easy to use and quick to implement. The calculated score-
sensitivity and specificity is 84 and 80% (on day 4), respectively. 
Despite the most predictive value of the clinical score for the 
development of hsPDA between days 3 and 4, the score can be 
used from day 2 on up to clinical stabilization (without needing 
respiratory support). Since the diagnosis of hsPDA is made by a 
summary of several echo-criteria in combination with the clini-
cal deterioration of the preterm neonate, this score allows for a 
more standardization in confirming this diagnosis. The continu-
ous assessment of these clinical parameters by using the PDA 
score also allows for a more targeted use of echocardiography, 
and might help to reduce the number of ultrasound examina-
tions in preterm neonates.
eThics sTaTeMenT
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the 
institutional and/or national research committee and with 
the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. Permission for this study was 
approved by the hospital’s Human Ethics Research Committee 
(EK359112010).
aUThOr cOnTriBUTiOns
AK collected data and performed analysis and critically revised 
content of manuscript. BS collected data and critically revised 
con tent of manuscript. AH collected data and critically revised 
content of manuscript. UR helped with the statistical analysis 
of the data and critically revised content of manuscript. MR 
supported conceptualizing study design and critically revised 
TaBle 2 | Clinical PDA score parameters.
significant clinical parameters
Day of 
life
2 3 4 5 6 7 8 9 10
PP 1.0 0.027 0.026 0.120 0.738 1.0 0.171 0.292 1.0
HR 0.261 1.0 0.589 0.204 0.168 1.0 1.0 0.706 1.0
A/MV 0.698 0.033 0.782 0.029 0.098 0.715 0.201 0.610 1.0
FP 0.357 0.038 0.021 0.186 0.159 0.244 1.0 0.542 1.0
SM 0.761 0.221 0.061 0.339 0.339 0.552 1.0 0.542 0.269
HM – – 1.0 1.0 – – – – 0.185
AC 0.030 0.005 0.033 0.401 0.039 0.055 0.057 0.121 1.0
PD 1.0 0.609 1.0 1.0 1.0 1.0 1.0 0.102 0.318
Significance of clinical parameters compared to the diagnosis of hsPDA by 
echocardiography. p-Values < 0.05 were considered statistically significant.
PP, pulsations of the precordium; HR, heart rate; A/MV, apnea or mechanical 
ventilation; FP, femoral pulses; SM, systolic murmur; HM, hepatomegaly; AC, acidosis; 
PD, pulmonary deterioration.
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